Carboplatin Injection Shortage: FDA Alert
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Carboplatin Injection, an oncology medication, is currently in shortage with some manufacturers reporting limited availability or discontinuation, as per FDA data.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Carboplatin.
Carboplatin Injection Shortage Update
What's in Shortage
The generic drug Carboplatin Injection, also known by the brand name CARBOPLATIN, is currently in shortage. It is an injection dosage form used in oncology treatments. The shortage status is 'Current', with the initial posting date of 04/28/2023 and last updated on 03/27/2026.
Which Manufacturers Are Affected
- Hospira, Inc., a Pfizer Company: For Carboplatin Injection, 600 mg/60 mL (10 mg/mL), availability is Limited Availability, with next delivery in April 2026 and estimated recovery in June 2026 due to manufacturing delay. Contact: 844-646-4398. For other presentations like 50 mg/5 mL (10 mg/mL) under NDC 61703-339-18, 50 mg/5 mL (10 mg/mL) under NDC 61703-360-18, 150 mg/15 mL (10 mg/mL) under NDC 61703-150-05, 450 mg/45 mL (10 mg/mL) under NDC 61703-339-50, 150 mg/15 mL (10 mg/mL) under NDC 61703-339-22, 600 mg/60 mL (10 mg/mL) under NDC 61703-600-05, and 450 mg/45 mL (10 mg/mL) under NDC 61703-262-05, it is Available. Contact: 844-646-4398.
- Teyro Labs: For Carboplatin Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) and 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1), availability is Unavailable due to discontinuation of manufacture. Contact: Apotex Inc. at 800-706-5575.
Why There's a Shortage
The reason for the shortage is listed as 'Other' by the FDA. No additional details were provided.
What Patients Should Do
Patients who depend on Carboplatin Injection should speak with their healthcare provider or pharmacist about the current availability. They can inquire about potential options and contact the relevant manufacturer for further information. Please remember that this is not medical advice; always consult your healthcare provider before making any changes to your treatment.
Source
This information is sourced from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,902 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.